

Imaging Tri-Fusion Multimodality Reporter Gene Expression in Living Subjects

Pritha Ray,^{1,5} Abhijit De,^{1,5} Jung-Jun Min,¹ Roger Y. Tsien,⁴ and Sanjiv S. Gambhir^{1,2,3,5}

¹Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California; ²University of California Los Angeles-Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California; ³Department of Biomathematics, David Geffen School of Medicine, University of California, Los Angeles, California; ⁴Howard Hughes Medical Institute and Department of Pharmacology, University of California, San Diego, California; and ⁵Department of Radiology and the Bio-X Program, Stanford University

ABSTRACT

Imaging reporter gene expression in living subjects with various imaging modalities is a rapidly accelerating area of research. Applications of these technologies to cancer research, gene therapy, and transgenic models are rapidly expanding. We report construction and testing of several triple fusion reporter genes compatible with bioluminescence, fluorescence and positron emission tomography (PET) imaging. A triple fusion reporter vector harboring a bioluminescence synthetic *Renilla* luciferase (*hrl*) reporter gene, a reporter gene encoding the monomeric red fluorescence protein (*mrfp1*), and a mutant herpes simplex virus type 1 sr39 thymidine kinase [*HSV1-truncated sr39tk* (*ttk*); a PET reporter gene] was found to preserve the most activity for each protein component and was therefore investigated in detail. After validating the activities of all three proteins encoded by the fusion gene in cell culture, we imaged living mice bearing 293T cells transiently expressing the *hrl-mrfp-ttk* vector by microPET and using a highly sensitive cooled charge-coupled device camera compatible with both bioluminescence and fluorescence imaging. A lentiviral vector carrying the triple fusion reporter gene was constructed and used to isolate stable expressers by fluorescence-activated cell sorting. These stable 293T cells were further used to show good correlation ($R^2 \sim 0.74-0.85$) of signal from each component by imaging tumor xenografts in living mice with all three modalities. Furthermore, metastases of a human melanoma cell line (A375M) stably expressing the triple fusion were imaged by microPET and optical technologies over a 40–50-day time period in living mice. Imaging of reporter gene expression from single cells to living animals with the help of a single tri-fusion reporter gene will have the potential to accelerate translational cancer research.

INTRODUCTION

To unravel the complexity and dynamics of molecular and cellular events, it is desirable to image reporter gene expression in individual cells, living animals, and humans with the help of a single reporter gene construct. Noninvasive and repetitive imaging of molecular events within a single cell to groups of cells within a living subject using different imaging modalities should play a critical role in understanding normal physiology and disease progression (1). Fluorescent reporter genes such as green fluorescence protein (*gfp*), red fluorescent protein (*rfp*), and their various mutants have been used extensively to tag individual proteins or cells, to monitor biochemical interactions of proteins and cell trafficking, and to study cellular dynamics (2). Expression of these fluorescent proteins in living cells can be imaged in real time by confocal laser microscopy, two-photon laser microscopy, and several other advanced microscopy techniques. On the other hand, noninvasive imaging of reporter gene expression in living subjects can be accomplished by using positron emission tomography (PET), single-photon emission computed tomography,

magnetic resonance imaging, and small animal optical imaging modalities with distinct reporter genes compatible with each imaging modality (1, 3, 4). All of these noninvasive imaging modalities are playing expanding roles in the biomedical sciences. Imaging of reporter gene expression by PET is being used to directly and indirectly monitor therapeutic gene expression, immune cell trafficking, and protein-protein interactions (1). Noninvasive optical imaging techniques such as bioluminescence (5) and fluorescence (6) are also being applied in many ways including imaging critical pathways involved in tumorigenesis and metastasis (1). However, each of these imaging techniques and their respective reporter genes has unique advantages and limitations (1). The optical imaging strategies have the advantages of being relatively low cost and high-throughput, but they are limited by their nontomographic nature, lack of fine spatial resolution, and inability to scale up to larger animals and humans. PET has the advantage of being applicable to all living subjects, but it has the disadvantage of requiring relatively short-lived radioactive tracers. Bioluminescence, although relatively easy to perform in small animals, is difficult to use for single cell imaging, whereas fluorescence is highly sensitive for single cell imaging.

A specific strategy for combining the different modalities, including a cell-based technique with an animal imaging technique, is to build a unified fusion gene composed of different reporter genes whose expression can be imaged with different imaging modalities in both individual cells and living subjects. This approach is useful, provided that the fusion protein could retain at least moderate levels of activity of each individual reporter protein and be stable and not broken down into its specific constituents. This approach also opens the possibility of merging PET and optical imaging techniques for applications in a single living subject. Previously, we reported construction and validation of a fusion reporter vector bearing HSV1-sr39 thymidine kinase and *Renilla* luciferase (*tk_{20r1}*) joined by a 20-amino acid (aa)-long spacer for imaging with microPET and bioluminescence optical charge-coupled device (CCD) modalities in living mice (7). This strategy was limited by the inability to image individual cells due to the relatively low light yield from bioluminescence. In the current study, we developed and tested several triple fusion vectors bearing a bioluminescence, a fluorescence, and a PET reporter gene joined by a 14-aa-long and an 8-aa-long spacer, respectively. Among all of the vectors tested, *hrl-mrfp-ttk* triple fusion reporter vector containing a synthetic *Renilla* luciferase [*hrl* (8)], monomeric rfp [*mrfp1* (9)], and a truncated version of sr39tk (*ttk*; the first 135 bp of *sr39tk* were deleted) could best preserve the activities of all three component proteins and was therefore pursued for additional studies. We then imaged reporter gene expression in individual living cells by inverted fluorescence microscopy and also in living mice by both microPET and a cooled CCD camera compatible with both bioluminescence and fluorescence imaging. We also developed a lentiviral vector carrying the triple fusion reporter construct to infect dividing and nondividing cells and isolated stable expressers of 293T cells by fluorescence-activated cell sorting (FACS). Finally, we used a cancer metastatic model by introducing human melanoma cells (A375M) stably expressing the triple fusion reporter gene in living mice via tail vein and imaged metastases over a period of 50 days by all three of

Received 6/19/03; revised 11/6/03; accepted 12/5/03.

Grant support: Grant DE-FG03-01ER63276 (to R. Y. Tsien); NIH Grants P50 CA86306 (to S. S. Gambhir), R01 CA82214 (to S. S. Gambhir), and SAIRP R24 CA92865 (to S. S. Gambhir); and Department of Energy Contracts DE-FC03-87ER60615 and DE-FG02-03ER63687 (to S. S. Gambhir).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Sanjiv S. Gambhir, Stanford University, The James H. Clark Center, 318 Campus Drive, East Wing, First Floor, Stanford, California 94305-5427. E-mail: sgambhir@stanford.edu.

the imaging modalities. The unique tri-fusion vector should facilitate rapid translation of approaches developed in cells to preclinical models and, eventually, clinical applications.

MATERIALS AND METHODS

Chemicals. [^3H]Penciclovir and ^{14}C -labeled 2'-fluoro-5-fluoro-1- β -D-arabinofuranosyluracil were obtained from Moravek Biochemicals (Brea, CA). 9-(4-[^{18}F]Fluoro-3-hydroxymethylbutyl)guanine (FHBG) was also synthesized at University of California Los Angeles as detailed previously (10). Coelenterazine was purchased from Biotium, Inc. (Hayward, CA). The polyclonal anti-TK antibody was a kind gift of Dr. M. Black (Washington State University, Pullman, WA), and the monoclonal anti-*Renilla* luciferase protein (RL) was purchased from Chemicon International (Temecula, CA).

Construction of *hrl-mrfp-ttk* and Other Fusion Genes. PCR amplification and standard cloning techniques were used to insert the *hrl* and *mrfp* genes from plasmid pCDNA 3.1-*CMV-hrl* (Promega, Madison, WI) and pCDNA3.1-*CMV-mrfp1* in frame with the *ttk* gene into the pCDNA3.1-*sr39-truncated tk* (a kind gift of Dr. D. Kaufman; University of California, Los Angeles, CA). The *CMV-wtk* vector was obtained from Dr. M. Black and modified to truncated *wtk* (*wtkk*) by deleting first 135 bp through PCR and cloned in pCDNA3.1 backbone to generate *CMV-wtkk* plasmid. *CMV-fl* and *CMV-egfp* were purchased from Promega and BD Sciences-Clontech (Palo Alto, CA) respectively. For PCR amplifications, different 5' and 3' end primers were used to generate the fusion vectors. Standard cloning techniques were used to generate the lentiviral (CS-*hrl-mrfp-ttk*) vector as performed previously in our laboratory (11).

Cell Lines and Transient Transfection Procedures. Neuro 2a (N2a) neuronal cell lines (a gift from Dr. Vincent Mauro; Scripps Research Institute, La Jolla, CA), 293T human embryonic kidney cells (American Type Culture Collection, Manassas, VA), and A375M human melanoma cells (a gift from Dr. M. Kolodny; University of California, Los Angeles, CA) were used. The N2a and A375M cells were cultured in high-glucose DMEM supplemented with 10% fetal bovine serum and 1% penicillin (100 $\mu\text{g}/\text{ml}$) and streptomycin (292 $\mu\text{g}/\text{ml}$), and 293T cells were grown in MEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin solution. All transient transfections were carried out using the Superfect transfection reagent (Qiagen, Valencia, CA) following the protocol recommended by the manufacturer.

tTK, hRL, and β -Galactosidase (β -Gal) Activity. TK enzyme activity assays were performed as described previously (12), and β -Gal and *Renilla* or firefly luciferase assays were done using the β -Gal enzyme assay system and Dual-Luciferase Reporter Assay System from Promega, respectively. Each of the luciferase reactions was measured in a TD 20/20 luminometer (Turner Designs, Sunnyvale, CA) for a period of 10 s.

Western Blot Analysis. The levels of tTK and hRL were evaluated by Western blotting with a rabbit polyclonal anti-TK antiserum and a mouse monoclonal anti-*Renilla* antibody using cell lysates prepared from 293T cells transfected with *CMV-hrl-mrfp-ttk*, *CMV-ttk*, and *CMV-hrl* plasmids (12).

Lentiviral Production. Lentivirus was developed and used to infect 293T and A375M cells as described previously (11).

Fluorescence Microscopy, CCD Imaging, and FACS. Expression of mRFP1 was observed under a Zeiss Axiovert 200M fluorescence microscope (Carl Zeiss Microimaging Inc., Thornwood, NY) with DsRed filter setting (λ_{ex} , 546 nm; λ_{em} , 605 nm) and analyzed with MetaMorph software (University Imaging Corp., Downingtown, PA). For quantification of the expression level of mRFP1 present in the *CMV-hrl-mrfp-ttk* and *CMV-mrfp1*, 1×10^4 and 1×10^5 of 293T, A375M, or N2a cells expressing the vectors were seeded in black-bottom clear 96-well plates and imaged in the Xenogen IVIS optical imaging system (Xenogen Corp., Alameda, CA) with an excitation filter at 500–550 nm and an emission filter at 575–650 nm. Regions of interest (ROIs) were drawn over the cell area and quantified by using Living Image Software version 2.20. For FACS, 1×10^6 of CS-*hrl-mrfp-ttk* infected 293T and A375M cells were sorted by using a Becton Dickinson FACSvantage SE cell sorter.

MicroPET Imaging of Mice. Animal care and euthanasia were performed with the approval of the University of California Animal Research Committee. Male 12–14-week-old nude mice (nu/nu) received s.c. injection with $\sim 10 \times 10^6$ 293T cells transiently expressing the *CMV-hrl-mrfp-ttk* fusion,

CMV-ttk, *CMV-hrl*, and *CMV-mrfp1* on the ventral side, and mice ($n = 4$) were scanned the next day using a microPET as described previously (12). Additionally, 10×10^6 of each of four differentially expressing clones of 293T cells stably expressing *hrl-mrfp-ttk* gene were implanted in three mice and scanned in the microPET ~ 24 h later. The microPET images were reconstructed by using three-dimensional filtered back projection and an iterative maximum *a posteriori* algorithm (13). ROIs were drawn over the tumor area. The ROI counts were converted to percentage of injected dose/g (ID/g) using filtered back projection as described previously (12), and images shown were reconstructed with maximum *a posteriori* algorithm.

Bioluminescence and Fluorescence Imaging of mRFP1 and RL Expression in Living Mice. For *in vivo* fluorescence imaging, mice implanted with the cells described above were anesthetized, and each mouse was placed in a light tight chamber equipped with a halogen light source, and whole body image was acquired for 1 s using the Xenogen IVIS optical imaging system with an excitation filter at 500–550 nm and an emission filter at 575–650 nm. ROIs were drawn over implanted cell area and quantified by using Living Image Software version 2.20. For bioluminescence imaging, each mouse next received injection with 10 μl (2 $\mu\text{g}/\mu\text{l}$ dissolved in methanol) of coelenterazine diluted in 90 μl of PBS (pH 7) via tail vein. Each animal was then placed supine in the same light tight chamber, and whole body images were obtained and quantified as described previously (8). Both bioluminescence and fluorescence signals were recorded as maximum [photons/second/centimeter²/steradian (photons/s/cm²/sr)].

Multimodality Imaging of Cancer Metastasis in Living Mice Using a Human Melanoma Cell Line (A375M) Stably Expressing the Triple Fusion Vector. Three 8-week-old Beige severe combined immunodeficient mice received injection with 7×10^5 A375M cells stably expressing the *hrl-mrfp-ttk* gene via tail vein and were imaged repeatedly with fluorescence, bioluminescence, and microPET. At day 40, the mice were first imaged with microPET and bioluminescence (as described above) and then sacrificed and imaged; the chest was cut open with Illuminatioo Tunable lighting system using the 540 nm excitation filter and RFP viewing glass (Lighttools Research). Fluorescence imaging and light photograph of mice were digitally captured with a Nikon camera for 2 s.

RESULTS

A Multimodality Fusion Vector Harboring the *hrl* Gene (Bioluminescence), Gene Encoding for mRFP1 (Fluorescence), and a Mutant Truncated HSV1-sr39 Thymidine Kinase (PET) Reporter Gene Maintains hRL, mRFP1, and tTK Activity in Several Cell Lines. We first constructed a fusion gene vector (*hrl-ttk*) carrying *hrl* (*hrl*, gene; hRL, enzyme) and *ttk* (*ttk*, gene; tTK, enzyme) reporter genes separated by a 22-aa-long spacer (LENSHASAGYQACGTAG-PGSTG) and then inserted the PCR-amplified *mrfp1* gene fragment in the middle of the spacer (at the position of Cys-Gly) to generate a *hrl-mrfp-ttk* triple fusion reporter gene. The PCR-amplified *hrl* gene fragments from pCMV-*hrl* vector were inserted in frame with *ttk* gene (the first 45 aa of *sr39tk* gene were truncated to delete the nuclear localization signal of *tk* gene) cloned in pCDNA3.1+ separated by the above-mentioned spacer under the control of a CMV promoter. The resultant vector was then digested with *Hind*III and *Sac*II and ligated in frame to PCR-amplified and *Hind*III/*Sac*II-digested *mrfp1* fragments (without stop codon) from pRSETB vector to generate the *hrl-mrfp-ttk* fusion vector. The order of the three different reporter genes and spacers in this triple fusion vector is as follows: *hrl*-spacer (LENSHASAGYQAST)-*mrfp*-spacer (TAGPGSAT)-*ttk* gene. The final vector was fully verified by sequencing.

Plasmid DNA prepared from four to five clones of *CMV-hrl-mrfp-ttk* triple fusion were transiently transfected in 293T cells, and the cells were first observed in a fluorescence microscope for mRFP1 activity and further assayed for hRL and tTK activity. The plasmid clone exhibiting the highest mRFP1, hRL, and tTK activities was selected for additional studies. To extend our study to different variants of bioluminescence/fluorescence/PET reporter genes, we also

generated several functionally active multimodality reporter fusion vectors, *i.e.*, *fl-mrfp-ttk* [by replacing *hrl* with firefly luciferase (*fl*)], *fl/hrl-egfp/rfp-ttk* (*mrfp1* is replaced with *egfp* or tetrameric *rfp* known as DsRed2), and *fl/hrl-rfp-wttk* [by replacing the truncated HSV1-sr39tk (*ttk*) with wild-type HSV1-truncated thymidine kinase (*wttk*)]. The nature and the order of the spacers for all these constructs were equivalent to CMV-*hrl-mrfp-ttk* vector described earlier. The *ttk*, *wttk*, *fl*, *hrl*, *rfp*, *gfp*, and *mrfp1* genes were also cloned in pCDNA3.1+ backbone to generate positive control plasmids to directly compare the results of each fusion. All these fusion vectors were functionally active with respect to each individual protein, however the level of activity varied for each construct (Table 1). Overall, the *hrl-mrfp-ttk* fusion construct showed the highest activity for all three of the component proteins in comparison with other vectors and thus was further studied for multimodality imaging.

To compare the levels of reporter gene expression of each of the components of the CMV-*hrl-mrfp-ttk* plasmid, three different cell lines [293T, N2a, and A375M (Fig. 1, A–C)] were transiently transfected with the triple fusion plasmid along with proper positive controls (pCDNA3.1-*ttk*, pCDNA3.1-*mrfp1*, pCDNA3.1-*hrl*) and negative controls (mock-transfected control cells). Each cell line was also cotransfected with the CMV- β -gal reporter gene to normalize for transfection efficiency. After 24 h, the expression of *mrfp1* was observed in the inverted fluorescence microscope, and then activity of the other three reporter genes was assayed from the same cell lysates, and tTK and hRL activities were normalized to β -Gal activity. In all three of the different cell lines, CMV-*hrl-mrfp-ttk* showed equal or slightly higher tTK activity (not statistically significant) compared with the positive control (pCDNA3.1-*ttk*) but had a lower hRL activity [33% (A375M), 27.4% (N2a), and 54% (293T)] compared with that of the positive control pCDNA3.1-*hrl* plasmid ($P < 0.05$). The expression level of *mrfp1* of this triple fusion vector in all of the cell lines was ~60–70% of the positive control pCDNA3.1-*mrfp1* vector, as determined by the fluorescence signal using the CCD camera.

Western Blot Analysis of Extracts from Cells Transiently Transfected with *hrl-mrfp-ttk* Probed with Anti-TK and Anti-RL Antibodies Reveals the Presence of a 100-kDa Fragment, the Predicted Size of the Protein Encoded by the *hrl-mrfp-ttk* Fusion. To investigate *hrl-mrfp-ttk* fusion reporter gene expression at the protein level, cell lysates from *hrl-mrfp-ttk*-, *ttk*-, and *hrl*-transfected 293T cells were resolved by 10% SDS-PAGE and analyzed on Western blots by using antibodies specific for TK and RL (Fig. 2A). The predominant band in the triple fusion sample recognized by anti-TK (Fig. 2A.1) and anti-RL (Fig. 2A.2) antibodies is about 100 kDa, the expected size of the hRL-mRFP-tTK fusion protein. The tTK and the hRL proteins were recognized at about 36 kDa band by their specific

antibodies. Similar results were also obtained from N2a and A375M cell extracts (data not shown).

A Lentiviral Vector Carrying the *hrl-mrfp-ttk* Triple Fusion Is Able to Stably Transfect 293T and A375M Cells, and the Positive Expressers Can Be Sorted by FACS Analysis. One potential use of a lentiviral vector is to deliver the genes of interest to any type of dividing or nondividing cell lines or target tissues in living animals. Therefore, the full-length fusion gene cassette was cloned in the *NheI* and *XhoI* site of a second-generation lentiviral vector (11), and viruses carrying the triple fusion reporter gene were used to transduce 293T cells. Five million 293T cells infected with lentivirus were sorted by FACS using a 585 ± 42 nm filter setting, and 33% positive expressers were collected (Fig. 2B.1). The sorted and unsorted cells were then assayed for tTK and hRL expression (Fig. 2B.2) and clearly show a significant ($P < 0.05$) gain in expression in the sorted cell population. Similarly, the A375M cells were transduced with the lentivirus carrying the triple fusion reporter gene, and positive expressers were selected by two rounds of FACS sorting and verified to have significant hRL and tTK activities (data not shown).


293T Cells Transiently Expressing the *hrl-mrfp-ttk* Fusion Reporter Gene Can Be Imaged in Living Mice with the MicroPET and Optical Cooled CCD Imaging Systems. Our aim of building a fusion reporter vector was to test its efficacy for simultaneous imaging of reporter gene expression quantitatively and repeatedly in living subjects using different modalities. We therefore injected 10×10^6 293T cells transiently transfected with either CMV-*hrl-mrfp-ttk*, CMV-*ttk*, CMV-*hrl*, or CMV-*mrfp1* vectors *s.c.* at four different sites on the ventral sides of four 12–14-week-old nu/nu nude mice. The mice were first scanned using the cooled CCD camera for fluorescence followed by a bioluminescence scan after injection of 20 μ g of coelenterazine via tail vein. Fluorescence imaging of these mice reveals that the cells expressing the *hrl-mrfp-ttk* fusion (Fig. 3A.1, a) show lower fluorescence [$\sim 11.03 \pm 6.03 \times 10^8$ maximum (p/s/cm²/sr)] in comparison with the cells expressing *mrfp1* vector (Fig. 3A.1, c) alone [$\sim 65.8 \pm 32.29 \times 10^8$ maximum (p/s/cm²/sr); Fig. 3A.1]. No significant signal is observed from the other two sites of implantation carrying the CMV-*ttk* (Fig. 3A.1, b)- and CMV-*hrl* (Fig. 3A.1, d)-expressing cells. A bioluminescence scan of the mice shows a signal of $5.8 \pm 3.7 \times 10^6$ maximum (p/s/cm²/sr) from the cells expressing the fusion reporter gene (Fig. 3A.2, a) and about $7.37 \pm 4 \times 10^6$ maximum (p/s/cm²/sr) from the CMV-*hrl*-expressing cells (Fig. 3A.2, d). Similar to fluorescence imaging, the other two sites carrying CMV-*mrfp1* (Fig. 3A.2, c)- and CMV-*ttk* (Fig. 3A.2, b)-expressing cells did not show any significant bioluminescence signal. Because the FHBG mass used for PET imaging is 1000-fold lower (due to the presence of radioactive isotope) than the coelenterazine mass

Table 1 Fluorescent, bioluminescent and PET^a reporter gene expressions exhibited by different triple fusion constructs in comparison to the respective positive controls assayed from transiently transfected 293T cells (tTK and hRL activities are normalized with cotransfected β -Gal activity)

Constructs	% TK activity	% wTK activity	% hRL activity	% FL activity	RFP/eGFP/mRFP (fluorescence activity by microscopy)
<i>hrl-rfp-ttk</i>	39.7		27.8		Medium
<i>fl-rfp-ttk</i>	29.6			22.1	Low
<i>hrl-egfp-ttk</i>	50		33		High
<i>fl-egfp-ttk</i>	43			20	High
<i>hrl-mrfp-ttk</i>	149		54		High
<i>fl-mrfp-ttk</i>	100			53.6	Medium
<i>hrl-rfp-wttk</i>		76	44.7		Medium
<i>fl-rfp-wttk</i>		61.6		62.6	Low
<i>ttk</i>	100				
<i>wttk</i>		100			
<i>hrl</i>			100		
<i>fl</i>				100	
<i>mrfp1</i>					Very high

^a PET, positron emission tomography; eGFP, enhanced green fluorescence protein; β -Gal, β -galactosidase.

Fig. 1. mRFP1, hRL, and tTK activity exhibited by 293T, N2a, and A375M cell lines transiently transfected with the *hrl-mrfp-ttk* fusion construct. 293T (A), N2a (B), and A375M (C) cells were transiently cotransfected with CMV- β -gal and either CMV-*hrl-mrfp-ttk*, CMV-*ttk*, CMV-*hrl*, or CMV-*mrfp1*; harvested 24 h later; and assayed for mRFP1 expression (A.1, B.1, and C.1; by fluorescence microscopy) and tTK/hRL enzyme activities (A.2, B.2, and C.2). Bars for the fluorescence micrographs represent 100 μ m. Values for tTK and hRL activity were normalized with β -galactosidase activity for each transfection. The tTK activity is expressed as (percentage of conversion of [3 H]penciclovir to its phosphorylated form)/ μ g protein/min. The hRL activity is expressed as relative light units (RLU)/ μ g protein. Error bars represent SE for triplicate measurements. The slightly higher tTK activity exhibited by the hRL-mRFP-tTK fusion protein in comparison with the positive tTK protein is not statistically significant; however, the hRL activity of the hRL-mRFP-tTK fusion protein is significantly lower ($P < 0.05$) than the positive hRL protein.



used for bioluminescence imaging, PET imaging is not as sensitive as bioluminescence at superficial depths (1). Furthermore, PET imaging benefits from well-vascularized tissues with relatively high levels of reporter gene expression. We therefore implanted the cells expressing the fusion gene and *ttk* gene in the right and left axillary region of the mice. We quantified the signal from each of the sites expressing the CMV-*hrl-mrfp-ttk* and CMV-*ttk* directly from the microPET images to determine the percentage of ID/g tumor for FHBG. This percentage of ID/g is a measure of the amount of tracer accumulated in a given tissue site normalized to the injected amount and to the mass of the tissue examined. The mean percentage of ID/g for FHBG accumulation in the CMV-*hrl-mrfp-ttk*-expressing cells (0.303 ± 0.09 ; Fig. 3A.3, a and Fig. 3A.4, a) did not differ significantly from that of the CMV-*ttk*-expressing cells (0.313 ± 0.09 ; Fig. 3A.3, b and Fig. 3A.4, b) for the four mice (Fig. 3A.3 and 3A.4). Preservation of a high level of tTK activity and moderate levels of hRL and mRFP1 activities by this tri-fusion vector thus allows simultaneous imaging of transient expression of all three of the reporter genes in living mice with all three of the imaging techniques. Repetitive imaging of the same mouse over a 10-day period produced signals for all three of the reporter genes that increased with time as the tumor burden increased (data not shown).

The lentivirus-infected 293T cells stably expressing the *hrl-mrfp-ttk* fusion gene described in the previous section were diluted to single cells, and four clones with differential expression of all three genes were selected. In cell culture, these four clones exhibited good correlation between tTK and hRL ($R^2 = 0.96$), hRL and mRFP1 ($R^2 = 0.94$), and tTK and mRFP1 ($R^2 = 0.86$) activities (data not

shown). For quantification of mRFP1 activity, 3.5×10^5 cells of each clone and 293T cells were seeded in black, clear-bottomed 96-well plates in triplicate and imaged in the CCD camera with DsRed2 excitation and emission filter options. ROIs were drawn on each well, and fluorescence was measured quantitatively for each group. The basal fluorescence exhibited by 293T cells was subtracted from the fluorescence of each well of each clone, and the mean of the three wells of each clone was taken as absolute fluorescence activity, expressed as maximum (p/s/cm²/sr) for each clone. tTK and hRL assays were performed as described earlier. To measure the correlation between the expression of the three reporter genes across three different imaging modalities, 10×10^6 cells of each clone were implanted on the two axillary regions on the ventral side of three nude mice (two clones in each mouse), and mice were imaged for fluorescence, bioluminescence, and microPET on the same day as described above. The fluorescence and bioluminescence signals and the percentage of ID/g values for FHBG of the *hrl-mrfp-ttk* expressing clones across the three mice were all well correlated: $R^2 = 0.85$ (hRL:tTK; Fig. 3B.1); $R^2 = 0.74$ (hRL:mRFP1; Fig. 3B.2); and $R^2 = 0.74$ (tTK:mRFP1; Fig. 3B.3).

Metastasis of A375M Human Melanoma Cells Expressing the *hrl-mrfp-ttk* Reporter Gene Can Be Imaged by MicroPET and an Optical CCD Camera in Living Mice. To apply the tri-fusion strategy to a relevant preclinical cancer study, we used a melanoma metastatic model. A375M human melanoma cells are known to metastasize to other organs once injected in the animal i.v. and form pulmonary and brain metastases with some rare occurrence of bone metastases (14, 15). A375M cells (7×10^5) stably expressing the *hrl-mrfp-ttk* reporter gene were injected in three 8-week-old Beige




Fig. 2. Biochemical and flow cytometric characterization of *hrl-mrfp-ttk* fusion reporter gene expression. A, Western blot analysis of hRL-mRFP-tTK fusion protein. Twenty μ g of total cellular protein obtained from the cell lysates of transiently transfected 293T cells with *hrl-mrfp-ttk*, *ttk*, and *hrl* plasmids were resolved in a 10% SDS polyacrylamide gel and transferred and probed with anti-TK (A.1) and anti-RL (A.2) antibodies. A 100-kDa band was specifically recognized by the antibodies only from the hRL-mRFP-tTK fusion samples. The polyclonal anti-TK and the monoclonal anti-RL antibody recognize tTK (second lane in A.1) and hRL (third lane in A.2) at about 36 kDa, respectively. B, flow cytometry plot and enzymatic activities of the positive expressors of CS-*hrl-mrfp-ttk* (lentiviral vector)-infected 293T cells. One million 293T cells were infected with CS-*hrl-mrfp-ttk* vector and sorted with fluorescence-activated cell sorting with a filter at 585 ± 42 nm band setting. Highly fluorescing cells ($\sim 33\%$) that migrated to the P3 sector (B.1) were collected and further tested for tTK and hRL enzyme activities (B.2). The sorted fraction showed higher tTK and hRL activities than the unsorted population. The TK activity is expressed as (percentage of conversion of [³H]penciclovir to its phosphorylated form)/ μ g protein/min. The RL activity is expressed as relative light units (RLU)/ μ g protein.

severe combined immunodeficient mice via tail vein. On the first day of cell injection, bioluminescence signal was detectable from the lungs (the primary route of cell migration; Fig. 4A), but not from microPET images (data not shown). The mice were then subsequently imaged over time every 6–7 days for a period of 40–50 days. At day 40, moderate microPET signal ($\sim 0.35\%$ ID/g) from the lungs and strong signal ($\sim 0.78\%$ ID/g) from the chest region are detected from one of the three mice (Fig. 4C). A corresponding bioluminescence signal (2×10^5 p/s/cm²/sr) is detected from the lungs of the same mouse on the same day (Fig. 4B). The relatively high PET signal from the chest region (Fig. 4C) is not evident with bioluminescence imaging (Fig. 4C), likely due to relatively poor penetration of light produced by *Renilla* luciferase from greater depths. A faint bioluminescence signal (5×10^3 p/s/cm²/sr) was also seen from the pelvic region of the mouse that was undetectable in microPET, likely due to hindrance by the nonspecific signal due to FHBG tracer clearance from the kidneys and gastrointestinal tract. *In vivo* fluorescence imaging of metastases did not produce good images due to significant autofluorescence caused by the presence of hair. However, when the mouse was sacrificed, and internal organs were exposed, several small metastatic tumors were found with fluorescence (Fig. 4E). Among the other two mice, one showed bioluminescence signal in the abdominal region at day 48; however we could not detect specific microPET signal, likely due to the presence of moderate levels of nonspecific signal resulting from the clearance of FHBG through kidneys and the gastrointestinal tract.

DISCUSSION

In this study, we report the construction of several novel triple fusion reporter genes including one harboring a bioluminescence reporter gene (synthetic *Renilla* luciferase), a fluorescence reporter gene (monomeric red fluorescence protein), and a PET reporter gene (truncated version of HSV1-sr39 thymidine kinase) and validate its application in living cells (cell microscopy and FACS) and in living mice using three different small animal imaging technologies (*in vivo* fluorescence, *in vivo* bioluminescence, and microPET). Use of bi-fusion reporter genes for molecular imaging has been validated previously by us (7) and by other investigators (16, 17). These previous approaches have been limited by the inability to image single cells (7) or to take advantage of the low background signal with bioluminescence (16) or the advantage of tomographic imaging with PET (17). However, the ability to have a fluorescence, bioluminescence, and PET signal provides the full spectrum of coverage needed for many reporter gene applications. One can use this tri-fusion reporter gene to sort cells and to image in small living animals using either fluorescence or bioluminescence and in larger subjects, including humans, using PET. The ability to move between imaging technologies without having to use a different reporter gene for each application will greatly simplify various biological models including transgenics, cell trafficking, anticancer pharmaceutical research, and gene therapy.

Although our previous bi-fusion reporter construct (*tk_{20rl}*) showed well-correlated expression of PET and bioluminescence imaging modalities (7), it was somewhat limited by decreased TK activity and was susceptible to enzymatic cleavage into its component proteins. By changing the orientation of the fusion partner in the current vector, we could gain a significant amount of TK activity, indicating that the COOH-terminal end of thymidine kinase protein may be crucial for ensuring TK enzyme activity. In contrast, the hRL activity of the current construct showed a decrease in enzyme activity as opposed to our previous vector, which showed a gain in RL activity. However, this new synthetic version of *Renilla* luciferase (hRL) is 40–50-fold more active than original *Renilla* luciferase (18), and therefore a drop in RL activity did not affect the efficacy of this vector significantly. Moreover, the *tk* gene in this triple fusion vector has a deletion of the first 135 bp that contains a nuclear localization signal and a cryptic testis-specific transcriptional start point (19, 20). Thus, this deletion leads to more cytoplasmic localization of TK enzyme, likely resulting in more TK activity (21) due to the availability of greater amount of substrate (FHBG). This deletion mutant will also likely overcome the problem of male sterility in transgenic mice carrying the thymidine kinase gene due to production of a shorter transcript in testis from a cryptic transcriptional initiation site (20) present in the first 135 bp of the gene. Another added advantage of this vector over our previous one and other vectors reported in the literature is that it can retain its integrity as a fusion protein when expressed, so that signal from each component of the tri-fusion protein will not be susceptible to problems related to cleavage. The absence of cleavage of the triple fusion vector is likely due to change of certain amino acids (Cys-Gly to Ser-Thr) present in the spacer in contrast to the previously reported 20-aa spacer of the *tk_{20rl}* vector.

In the process of building a better multimodality vector, we constructed several other fusion vectors (see Table 1). Most of these vectors had lower tTK, luciferase, and RFP activity, probably due to the inherent nature of RFP (DsRed2) of forming obligate tetramer for proper maturation of the fluorophores (22) present in the fusion genes. The tetrameric nature of RFP present in *hrl/fl-rfp-ttk* fusions might impose structural and functional constraints on the other partner proteins resulting in decreased TK and luciferase activity. Our *hrl/fl-egfp-ttk* vectors did show a better TK and luciferase activity than *hrl/fl-*




Fig. 3. Results of imaging living mice. **A**, fluorescence, bioluminescence, and micro-positron emission tomography (PET) imaging of *hrl-mrfp-ttk* expression in the same living nude mouse. Ten million 293T cells transiently expressing the *CMV-hrl-mrfp-ttk*, *CMV-ttk*, *CMV-mrfp1*, and *CMV-hrl* plasmids were implanted s.c. at four sites on the ventral side of a nude mouse and imaged the next day for fluorescence/bioluminescence and PET using a cooled charge-coupled device (CCD) camera and microPET, respectively. Fluorescence imaging was performed by placing the mouse in a CCD camera for 1 s, and a fluorescence image was acquired with an excitation filter at 500–550 nm and an emission filter at 575–650 nm. Cells expressing the fusion (*A.1, a*) and *mrfp1* (*A.1, c*) genes showed fluorescence, and the signal is recorded as maximum photons/sec/cm²/sr (*A.1*). The same mouse was then scanned in the CCD camera for bioluminescence after injection of coelenterazine via tail vein, and bioluminescence signal was found in cells expressing the fusion (*A.2, a*) and *hrl* (*A.2, d*) and recorded as maximum photons/sec/cm²/sr (*A.2*). After the optical scan, the same mouse was imaged by microPET using 9-(4-[¹⁸F]fluoro-3-hydroxymethylbutyl)guanine (FHBG). Cells expressing the fusion reporter gene (*A.3, a* and *A.4, a*) and *tk* gene (*A.3, b* and *A.4, b*) showed FHBG accumulation in coronal section (*A.3*) and trans-axial section (*A.4*). Nonspecific accumulation of tracer was found in the gastrointestinal tracts and bladder (attributable to clearance of FHBG; *A.3*). **B**, *in vivo* correlation of *hrl*, *mrfp1*, and *tk* gene expression exhibited by four clones of 293T cells stably but differentially expressing the *hrl-mrfp-ttk* fusion. Ten million cells of each clone were implanted on the axillary regions of the ventral side of three nude mice (two clones in each mouse), and after 24 h, mice were imaged by the cooled CCD camera and microPET. Plots of percentage of ID/g versus bioluminescence [expressed as maximum photons/second/centimeter²/steradian (p/s/cm²/sr); *B.1*], bioluminescence versus fluorescence (both expressed as maximum p/s/cm²/sr; *B.2*), and percentage of ID/g versus fluorescence (expressed as maximum p/s/cm²/sr; *B.3*) were obtained from the regions of interest drawn over the regions of cell implantation. Each of the six data points of each plot represents region of interest data from the fluorescence, bioluminescence, and microPET images of the same living mouse, with a total of three mice (2 points/mouse)

rfp-ttk vectors, due to the monomeric nature of eGFP proteins, but did not show better activity than the *hrl/fl-mrfp-ttk* fusion vectors. Moreover, the excitation and emission spectra of GFP (λ_{ex} , 489 nm; λ_{em} , 508 nm) is not as favorable for fluorescence imaging in living subjects as compared with RFP and mRFP because of the better penetration of red and near-infrared light in tissues (1). We also consistently observed a drop in tTK and RFP activity of the triple fusions with firefly luciferase in comparison with the fusions bearing *Renilla* luciferase. Fusion reporter vectors bearing truncated wild-type thymidine kinase also preserved a better wild-type thymidine kinase and luciferase activity (with both firefly and *Renilla*), and these vectors should be useful in the future when using other substrates (*e.g.*, 2'-fluoro-5-fluoro-1- β -D-arbinofuranosyluracil/2'-deoxy-2'-fluoro-5-fluoro-1- β -D-arbinofuranosyluracil) that are more sensitive when used with wild-type thymidine kinase (23). It is likely that one tri-fusion will not serve the needs for all applications, and investigators will need to choose from a library of tri-fusions for a given application.

One of the potential uses of the multimodality reporter vectors in gene therapy is to target any type of cell line or tissues and then follow gene expression using a multimodality approach. Viral vectors, especially the lentiviral ones, are among the most standardized and widely used vectors to deliver any gene of interest to target tissues or an organism and to isolate cells, particularly nondividing cells stably

expressing the gene. Recently, a bicistronic lentiviral vector carrying *tk* and *fl* reporter genes has been successfully used for PET and bioluminescence imaging in our laboratory (11). The new lentiviral construct carrying the triple fusion gene reported in this work has been used successfully with FACS analysis to isolate lentiviral infected 293T and A375M cells stably expressing the triple fusion reporter. This lentiviral construct should have tremendous potential in wide variety of research applications. Our preliminary data with the A375M metastatic melanoma model further confirm the usefulness of this lentiviral vector carrying triple fusion reporter gene to follow progression of cancer metastases by molecular imaging. Extensions of this study with drug treatment are currently in progress (24).

Use of light is probably the oldest method of analyzing tissues in biomedical science (25). The various optical imaging approaches including fluorescence microscopy (at the cellular level), diffuse optical tomography, and intravital microscopy (for deeper structures at the organism level) are commonly used (26, 27). However, intrinsic absorption and scattering of light through the tissues and autofluorescence properties of biological molecules (*e.g.*, tryptophan, collagen, elastin, nicotinic adenine dinucleotide, hemoglobin, oxyhemoglobin, and so forth) impose certain restrictions for using fluorescence as an imaging tool in small living subjects. However, both light attenuation and autofluorescence decline as wavelength increases,




Fig. 4. Multimodality imaging of metastasis of A375M cells stably expressing the *hrl-mrffp-ttk* fusion reporter gene in living mice. **A**, bioluminescence imaging of a SCID mouse injected with A375M cells expressing the *hrl-mrffp-ttk* vector at day 0. 7×10^5 A375M cells stably expressing the triple fusion were injected via tail-vein in a SCID mouse and two hours later imaged for bioluminescence signal following tail-vein injection of coelenterazine. Prominent bioluminescence signal was found from the region of both the lungs [$1.3\text{--}1.5 \times 10^5$ max (p/sec/cm²/sr)]. **B**, bioluminescence imaging of the same SCID mouse at day 40. At day 40, the same mouse was imaged and relatively high bioluminescence signal [2×10^5 max (p/sec/cm²/sr)] was found from the left lung region and moderate signal from the right lung region. A faint bioluminescence signal (5×10^3 p/sec/cm²/sr) was also present from the right pelvic region. **C**, microPET imaging of the same SCID mouse at day 40. Following a bioluminescence scan, the mouse was imaged in microPET using FHBG. Shown is a thin coronal slice of ~ 1 -mm thickness. A strong signal ($\sim 0.78\%$ ID/g) was present from the chest region (*Ch*) with lower signal (0.35% ID/g) from the lung region. The stronger PET signal was found to be from a metastatic tumor present deep inside the body, as evident from the fluorescence photograph (**E**). Note the gallbladder (*GB*) retains FHBG so background signal from the *GB* is also seen in the microPET images. **D**, light photograph of the same SCID mouse after sacrifice and organ exposure (image has been modified by using Adobe Photoshop version 6). **E**, whole body fluorescence imaging of the same SCID mouse. Fluorescing metastatic tumors were found in lung and chest regions that correspond with the bioluminescence and PET images.

especially in the red to near-infrared region (>600 nm). A fluorescence protein/fluorochrome with excitation and emission toward red (560 nm onward) has better penetrability through the tissues than that with excitation and emission in the blue or green region. Moreover, hemoglobin and water, which are responsible for the highest absorption of light among all other biological molecules, have their lowest coefficient of absorption in the red and near-infrared region. Therefore, *in vivo* fluorescence imaging is more suitable in the red and near-infrared region than in the green or yellow region. Optical imaging in living subjects at the near-infrared region (650–900 nm) has therefore been used extensively by applying different fluorochromes that emit light at near-infrared region spectra (28) and in combination with other imaging modalities (29). However, synthesis and attachment of these fluorochromes to proteins/copolymers require complex chemical procedures and are more difficult to generalize. Also, these strategies are not directly applicable to genetically encoded reporters. The mRFP1 protein used in this study has an excitation and emission range in the far-red region (584–607 nm) and thus is one of the better reporter gene choices for fluorescence imaging in living subjects (9). The monomeric nature of this protein also confers a better functional preservation as fusion partner as compared with RFP or DsRed2 (tetramer) and HcRed (dimer). However, we still observed a significant amount of autofluorescence from the mouse relative to bioluminescence, which is not limited by autofluorescence, and therefore bioluminescence produced a better signal:background ratio in living animals. However, bioluminescence imaging of gene expression in a single cell is not easily possible due to generation of relatively low amounts of light. Therefore, the current results would support using the fluorescence component for cell imaging/sorting with limited *in vivo* imaging, bioluminescence for small animal imaging even with a very few number of cells, and PET for tomographically imaging living subjects including larger animals and humans.

Our cancer metastatic model shows that metastases can be imaged by microPET and bioluminescence in living mice using this triple fusion reporter gene, with certain limitations for each technique. The bioluminescence signal from *Renilla* luciferase is not detectable from metastases present at greater depths but is easily detectable from superficial metastases from any region of the body. On the other hand, microPET reveals metastases from deep inside the body, but signals from metastases in the abdomen/pelvis are somewhat obscured by the

nonspecific signal in the gastrointestinal tract and urinary collecting system due to tracer clearance. Finally, autofluorescing properties of biological molecules limit detection of metastases by *in vivo* fluorescence imaging in living animals. However, metastases can be easily visualized in sacrificed animals with exposed tissues *in situ* using whole body fluorescence imaging. It is likely that the fluorescence signal to background can be improved by using an excitation source under the animal and imaging with a camera above the animal to help minimize autofluorescence. The bioluminescence signal can also be markedly improved by injecting higher doses of substrate (coelenterazine), as we have demonstrated recently (18). As red-shifted bioluminescent reporters with high substrate utilization capacity are developed, this will also likely aid in helping to use bioluminescence-based reporter fusions. In addition, the microPET signal can be improved by using tracers with longer half-lives (e.g., ¹²⁴I-labeled 2'-fluoro-5-fluoro-1- β -D-arabinofuranosyluracil) to allow the background signal from the gastrointestinal tract and renal collecting system to be reduced by waiting longer after tracer injection before imaging animals. With continued refinement in reporter genes, substrates for reporter proteins, and physical instrumentation, it is likely that higher spatial resolution imaging with greater sensitivity for detecting smaller numbers of cells will eventually be possible.

Additional studies quantitatively comparing fluorescence, bioluminescence, and PET in small living animals should also help to better define the potential roles of each modality in specific applications. Cancer research, including imaging of preclinical models of tumors and metastases, immune cell trafficking, transgenic models, gene therapy, and monitoring therapy in general should all benefit from the strategies developed in the current work.

ACKNOWLEDGMENTS

We thank W. Ladno, J. Edwards, X. Lewis, and D. Stout for technical assistance. We appreciate the kind help of Ian Chen and Shariar Yaghoubi. The members of the FACS core facility of University of California Los Angeles-Jonsson Comprehensive Cancer Center are duly acknowledged for their help.

REFERENCES

1. Massoud, T., and Gambhir, S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. *Genes Dev.*, 17: 545–580, 2003.

2. Van Roessel, P., and Brand, A. Imaging into the future: visualizing gene expression and protein interactions with fluorescent proteins. *Nat. Cell Biol.*, *4*: E15–E20, 2002.
3. Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. *Nat. Rev. Cancer*, *2*: 683–693, 2002.
4. Bremer, C., and Weissleder, R. *In vivo* imaging of gene expression. *Acad. Radiol.*, *8*: 15–23, 2001.
5. Vooijs, M., Jonkers, J., Lyons, S., and Berns, A. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. *Cancer Res.*, *62*: 1862–1867, 2002.
6. Bouvet, M., Wang, J., Nardin, S. R., Nassirpour, R., Meng Yang, Baranov, E., Jiang, P., Moossa, A. R., and Hoffman, R. M. Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. *Cancer Res.*, *62*: 1534–1540, 2002.
7. Ray, P., Wu, A., and Gambhir, S. Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. *Cancer Res.*, *63*: 1160–1165, 2003.
8. Bhaumik, S., and Gambhir, S. S. Optical imaging of *Renilla* luciferase reporter gene expression in living mice. *Proc. Natl. Acad. Sci. USA*, *99*: 377–382, 2002.
9. Campbell, R. E., Tour, O., Palmer, A. E., Steinbach, P. A., Geoffrey, S., Baird, G. S., David, A. Z., and Tsien, R. Y. A monomeric red fluorescent protein. *Proc. Natl. Acad. Sci. USA*, *99*: 7877–7882, 2002.
10. Yaghoubi, S., Barrio, J. R., Dahlbom, M., Iyer, M., Namavari, M., Satyamurthy, N., Goldman, R., Herschman, H. R., Phelps, M. E., and Gambhir, S. S. Human pharmacokinetic and dosimetry studies of [¹⁸F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. *J. Nucl. Med.*, *42*: 1225–1234, 2001.
11. De, A., Lewis, X. H., and Gambhir, S. S. Noninvasive imaging of lentiviral-mediated reporter gene expression in living mice. *Mol. Ther.*, *7*: 681–691, 2003.
12. Gambhir, S. S., Bauer, E., Black, M. E., Liang, Q., Kokoris, M. S., Barrio, J. R., Iyer, M., Namavari, M., Phelps, M. E., and Herschman, H. R. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. *Proc. Natl. Acad. Sci. USA*, *97*: 2785–2790, 2000.
13. Qi, J. Y., Leahy, R. M., Cherry, S. R., Chatzioannou, A., and Farquhar, T. H. High-resolution 3D Bayesian image reconstruction using the microPET small-animal scanner. *Phys. Med. Biol.*, *43*: 1001–1013, 1998.
14. Seftor, R. E., Seftor, E. A., and Hendrix, M. J. Molecular role(s) for integrins in human melanoma invasion. *Cancer Metastasis Rev.*, *18*: 359–375, 1999.
15. Giavazzi, R., Garofalo, A., Bani, M. R., Abbate, M., Ghezzi, P., Boraschi, P., Mantovani, A., and Dejana, E. Interleukin-1 induced augmentation of experimental metastases from a human melanoma in nude mice. *Cancer Res.*, *50*: 4771–4775, 1990.
16. Jacobs, A., Dubrovin, M., Hewett, J., Sena-Esteves, M., Tan, C. W., Slack, M., Sadelain, M., Breakefield, X. O., and Tjuvajev, J. G. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. *Neoplasia*, *1*: 154–161, 1999.
17. Wang, Y., Yu, Y., Shabahang, S., Wang, G., and Szalay, A. *Renilla* luciferase-*Aequorea* GFP (Ruc-GFP) fusion protein, a novel dual reporter for real-time imaging of gene expression in cell cultures and in live animals. *Mol. Genet. Genomics*, *268*: 160–168, 2002.
18. Bhaumik, S., Lewis, X. Z., and Gambhir, S. S. Optical imaging of synthetic *Renilla* luciferase reporter gene expression in living mice. *J. Biomed. Optics*, in press, 2004.
19. Degreve, B., Johansson, M., Declercq, E., Karlsson, A., and Balzarini, J. Differential intracellular compartmentalization of herpetic thymidine kinases (TKS) in TK gene-transfected tumor cells. Molecular characterization of the nuclear localization signal of the herpes simplex virus type 1 TK. *J. Virol.*, *72*: 9535–9543, 1998.
20. Cohen, J. L., Boyer, O., Salomon, B., Onclercq, R., Depetris, D., Lejeune, L., Dubus-Bonnet, V., Bruel, S., Charlotte, F., and Mattei, M. G. Fertile homozygous transgenic mice expressing a functional truncated herpes simplex thymidine kinase ΔTK gene. *Transgenic Res.*, *7*: 321–330, 1998.
21. Luker, G. D., Sharma, V., Pica, C. M., Dahlheimer, J. L., Li, W., Ochesky, J., Ryan, C. E., Piwnica-Worms, H., and Piwnica-Worms, D. Noninvasive imaging of protein-protein interactions in living animals. *Proc. Natl. Acad. Sci. USA*, *99*: 6961–6966, 2002.
22. Sacchetti, A., Subramaniam, V., Jovin, T., and Alberti, S. Oligomerization of DsRed is required for the generation of a functional red fluorescent chromophore. *FEBS Lett.*, *525*: 13–19, 2002.
23. Tjuvajev, J. G., Doubrovin, M., Akhurst, T., Cai, S., Balatoni, J., Alauddin, M. M., Finn, R., Bornmann, W., Thaler, H., Conti, P. S., and Blasberg, R. G. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. *J. Nucl. Med.*, *43*: 1072–1083, 2002.
24. De, A., Collison, E., Kolodney, M., and Gambhir, S. Lentiviral reporter gene delivery as a novel way of studying therapeutic effects on cancer metastasis by noninvasive imaging. *Mol. Ther.*, *7*: S137, 2003.
25. Anderssonengels, S., Afkinteborg, C., Svanberg, K., and Svanberg, S. *In vivo* fluorescence imaging for tissue diagnostics. *Phys. Med. Biol.*, *42*: 815–824, 1997.
26. Boas, D. A., Brooks, D. H., Miller, E. L., DiMarzio, C. A., Kilmer, M., Gaudette, R. J., and Zhang, Q. Imaging the body with diffuse optical tomography. *IEEE Signal Processing Magazine*, *18*: 57–75, 2001.
27. Jain, R. K., Munn, L. L., and Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. *Nat. Rev. Cancer*, *2*: 266–276, 2002.
28. Ntziachristos, V., Bremer, C., and Weissleder, R. Fluorescence imaging with near-infrared light: new technological advances that enable *in vivo* molecular imaging. *Eur. Radiol.*, *13*: 195–208, 2002.
29. Zaheer, A., Lenkinski, R. E., Mahmood, A., Jones, A. G., Cantley, L. C., and Frangioni, J. V. *In vivo* near-infrared fluorescence imaging of osteoblastic activity. *Nat. Biotechnol.*, *19*: 1148–1154, 2001.